IDAI vs ACXP vs PRAX vs AIOT vs CEVA

For growth investors, CEVA, Inc.

(CEVA) is the stronger pick with 9. 8% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Praxis Precision Medicines, Inc. (PRAX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Praxis Precision Medicines, Inc.

(PRAX) delivered a total return of -20. 8%, compared to -99. 1% for T Stamp Inc. (IDAI). Over 10 years, the gap is even starker: IDAI returned +102. 4% versus ACXP's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Praxis Precision Medicines, Inc.

(PRAX) is the lower-risk stock at 1. 55β versus CEVA, Inc. 's 2. 76β — meaning CEVA is approximately 78% more volatile than PRAX relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 130% for T Stamp Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CEVA, Inc.

(CEVA) is pulling ahead at 9. 8% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Acurx Pharmaceuticals, Inc. grew EPS 69. 8% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, AIOT leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Acurx Pharmaceuticals, Inc.

(ACXP) is the more profitable company, earning 0. 0% net margin versus -344. 1% for T Stamp Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACXP leads at 0. 0% versus -303. 9% for IDAI. At the gross margin level — before operating expenses — CEVA leads at 88. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AIOT: 135.

3% to $8. 00.

In this comparison, AIOT (22.

2% yield) pays a dividend. IDAI, ACXP, PRAX, CEVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, PowerFleet, Inc.

(AIOT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (22. 2% yield). Acurx Pharmaceuticals, Inc. (ACXP) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AIOT: -28. 7%, ACXP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IDAI (Technology) and ACXP (Healthcare) and PRAX (Healthcare) and AIOT (Technology) and CEVA (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IDAI is a small-cap quality compounder stock; ACXP is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; AIOT is a small-cap income-oriented stock; CEVA is a small-cap quality compounder stock. AIOT pays a dividend while IDAI, ACXP, PRAX, CEVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.